Basal-cell carcinomas (BCCs) are the most common cancer in Caucasians. It has been reported that the patched gene is inactivated in 30 ± 40% sporadic BCCs and 20% sporadic medulloblastomas via loss of heterozygosity and nonsense mutations. Recently, two activating smoothened mutations have been found in the sporadic basal cell carcinomas. One, at base pair 1604 (G-to-T transversion) of exon 9, changes codon 535 from tryptophan to leucine, and the other, at base pair 1685 (G-to-A transition) of exon 10, changes codon 562 from arginine to glutamine (Xie et al., 1998) . In our study, 1604G?T was found in 20 out of 97 (20.6%) sporadic BCCs. The high prevalence indicates that 1604G is the mutation hot spot in our tumor samples. This mutation was detected in all three histological subtypes of BCCs, suggesting that smoothened mutation is an early event during the development of the tumor. Our ®nding of a high smoothened mutation rate, together with high frequent patched gene mutations reported recently, indicates that activation of the hedgehog signal transduction pathway is the most common and early event in the development of sporadic BCCs. Additionally, to determine whether smoothened, like patched, is also involved in the carcinogenesis of medulloblastomas, we screened medulloblastoma samples for these two mutations by restriction analysis. We have found the 1604G?T mutation in 1 out of 21 medulloblastomas. This result con®rmed smoothened gene involvement in the carcinogenesis of medulloblastoma.
Keywords: hedgehog; patched; smoothened; basal cell carcinoma; mutation The current model of sonic hedgehog-patched-smoothened signaling exhibits a novel signal transduction mechanism. It has been hypothesized that in the absence of the Sonic hedgehog (Shh) signal, the membrane protein Patched (Ptch) represses the constitutive signaling activity of a second membrane protein, Smoothened (Smo), by virtue of its ability to form a Ptch-Smo complex (Stone et al., 1996) . Hence, mutations within the PTCH gene may result in the failure of Ptch to inhibit Smo, leading to constitutive activity of the Shh signaling pathway and to cancer, such as basal cell carcinomas , Hahn et al., 1996 and medulloblastomas (Rael et al., 1997) . While PTCH was known to be a tumor suppressor gene, SMO was only recently shown to be a proto-oncogene (Xie et al., 1998) .
Important advances in our understanding of human smoothened and basal cell carcinomas have been made following the isolation and characterization of the full-length cDNA and the genomic sequences for this membrane protein (Stone et al., 1996) . The human SMO gene is composed of 12 exons within 24 kb of genomic DNA and has been mapped to chromosome 7q31-32 by in situ hybridization. The protein consists of 787 amino acids and is a sevenspan transmembrane protein. Xie et al. (1998) detected two SMO gene mutations in sporadic BCCs. One, at base pair 1604 (G-to-T transversion) of exon 9 (numbering according to Genbank accession number U84401), changes codon 535 from tryptophan to leucine, and the other, at base pair 1685 (G-to-A transition) of exon 10, changes codon 562 from arginine to glutamine. Among the 47 studied sporadic BCCs in one study (Xie et al., 1998) , 1604G?T transversion was found in two BCC samples and 1685G?A transition was found in one BCC sample. Mutant Smo, unlike the wild type molecule, can cooperate with adenovirus E1A to transform rat embryonic ®broblast cells in culture. Furthermore, skin abnormalities similar to BCCs developed in transgenic murine skin over-expressing mutant Smo.
The exact mechanisms of carcinogenesis in basal cell carcinoma have yet to be elucidated. Over-expression of Shh is sucient to induce BCCs in mice, and the zinc-®nger transcription factor Gli1 is one of the downstream eectors in sporadic BCCs (Dahmane et al., 1997) , but the links between these events and malignancy remain unknown. In addition, it has been shown (Wicking et al., 1997) that there is no correlation between genotype and clinical phenotype for an identical PTCH gene mutation in three families having nevoid basal cell carcinoma syndrome (NBCCS), suggesting that phenotypic expression in NBCCS might be modulated by additional genes.
To determine the frequency and genotype-phenotype correlation of the two SMO mutations, we screened for these two mutations in our sporadic BCCs by restriction analysis and direct sequencing. We have tested the genotype-phenotype correlation by including all three histological subtypes of sporadic BCCs in our study. Additionally, to determine whether Smo, like Ptch, is also involved in the carcinogenesis of medulloblastomas, we screened medulloblastoma samples for these two mutations by restriction analysis.
A total of 97 formalin-®xed paran-embedded BCCs (72 nodular, 16 in®ltrative, four micronodular and ®ve super®cial spreading) from 97 patients were obtained from the Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, (Shatin, Hong Kong, China), Department of Pathology, Princess Margaret Hospital (Lai Chi Kok, Hong Kong, China) and Department of Pathology, United Christian Hospital (Kwun Tong, Hong Kong, China). In addition, fresh frozen tissues from 21 sporadic medulloblastomas from 21 patients were obtained from the Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, (Shatin, Hong Kong, China). Diagnoses of all tumors were con®rmed histologically. To assure that the tumor pieces taken for molecular genetic analysis contained a sucient proportion of tumor cells, a histological evaluation of a representative part of each of these pieces was performed. Peripheral blood samples were obtained with informed consent from 59 healthy volunteers who had no clinical symptoms or signs of basal cell carcinomas and medulloblastomas. All the studied subjects were of Chinese ancestry.
Tumor DNA was extracted from formalin-®xed paran-embedded and frozen sections by the Qiagen tissue extraction kit (Qiagen, Hilden, Germany) after micro-dissection to avoid gross contamination by nontumor cells. Paired germ-line DNA was extracted from normal skin tissues or peripheral blood of the same individuals. Genomic DNA was extracted from the peripheral blood samples using a salting out procedure (Lahiri and Nurnberger, 1991) .
The polymerase chain reaction was performed essentially as described (Xie et al., 1998) , and the SMO gene primers used were the same as reported (Xie et al., 1998) . For exon 9, 3 ml of the one-®fth diluted DNA was ampli®ed in a 20 ml reaction mixture containing 16Taq reaction buer (Gibco, BRL), 0.3 mg of each primer, 100 mmol/l of each of the four deoxynucleotides, 0.75 mmol/l magnesium chloride, 25 mmol/l TAPS (N-tris [Hydroxymethyl] methyl-3-aminopropanesulfonic acid), pH 9.3, 0.016% gelatin and 0.4 unit of Taq DNA polymerase (Gibco, BRL). DNA was then ampli®ed in a DNA thermal cycler 480 (Perkin Elmer, Foster City, CA, USA) with initial denaturation at 958C for 5 min, followed by 40 cycles of 948C for 30 s, 668C for 2 min and 728C for 1 min. The reaction was completed by a ®nal extension of the PCR products at 728C for 5 min. Fifteen ml aliquot of the PCR products was then digested with 10 units of BstN1 (New England Biolab, USA), in a total volume of 20 ml at 608C for 3 h according to the manufacturer's instructions. The digested products were then examined in a 6% polyacrylamide gel (acrylamide:bis-acrylamide, 19 : 1). The PCR products of the wild type allele contain two BstN1 restriction sites while the 1604G?T transversion abolishes one site and results in an extra fragment of size 42 bp larger than that from the wild type.
For exon 10, 1 ml of DNA in a total reaction volume of 10 ml was ampli®ed in a mixture of 16Taq reaction buer, 100 mmol/l deoxynucleotides, 0.2 mg of each primer, 1 mmol/l magnesium chloride, 0.1% W-1 (polyoxyethelene ether W-1) and 0.2 unit of Taq DNA polymerase (Gibco, BRL). The PCR program was similar to that described for exon 9 except that annealing was performed at 608C for 30 s. The total volume of PCR products was then digested with 2 units of AlwI (New England Biolabs) at 378C for 16 h. The mutation, 1685G?A transition, abolishes the only AlwI restriction site in the PCR products.
Direct sequencing of the PCR products was performed using the automated¯uorescence-based dideoxynucleotide termination method (model 310, Applied Biosystems, Foster City, CA, USA).
The 1604G?T mutation, identi®ed by BstNI restriction analysis, was detected in 20 out of 97 (20.6 %) sporadic BCCs, but was not detected in the corresponding normal skin tissues, con®rming that the mutation is somatic in origin. The nucleotide change was con®rmed by direct sequencing (Figure 1 ). In addition, the 1604G?T mutation was found in 1 out of 21 medulloblastomas, coming from a 3-year-old boy with classical midline cerebellar medulloblastoma, desmoplastic variant. In all tumors, the mutant sequence was present together with the wild type sequence; a ®nding supporting the role of smoothened as a proto-oncogene in the carcinogenesis of BCC. The 1604G?T mutation was not found, by restriction analysis, in 118 normal chromosomes.
The high prevalence of the 1604G?T transversion in our samples indicates that this mutation is important in the carcinogenesis of BCCs in our local population, and may be a mutational hot spot for the human SMO gene. The tryptophan residue at codon 535 is conserved among all described functional Smo protein sequences, is located in the seventh transmembrane domain, and corresponds to a conserved tyrosine residue in most G-protein coupled receptors (Scheer et al., 1997) . In the mouse model, activation of the hedgehog signaling pathway by over-expressing this mutant Smo molecule was con®rmed by the accumulation of large amounts of the mRNA of PTCH in Smoexpressing cells (Xie et al., 1998) .
Nineteen of the 20 mutations identi®ed in this study were found in tumors from sun-exposed sites, which we de®ned as the head and neck in both sexes, shoulders or chest in males and legs in females. Although this mis-sense mutation is not typical of ultraviolet-B (UVB) damage (e.g. C?T substitutions at dipyrimidine sites, including CC?TT double-base mutations (Brash et al., 1991 , Hutchinson et al., 1994 ), the 1604 G?T transversion can be caused by UV radiation. Other factors besides UV radiation could also be involved in the constitutive activation of the SMO gene but the available data do not implicate a speci®c environmental agent. Interestingly, basal cell carcinomas occur predominately in the Caucasian population (approximately 1 million new cases per year in the United States where BCC is the most common cancer), and much less in the Chinese population (approximately 200 new cases per year in Hong Kong (Mak et al., 1995) where BCC is not among even the ten most common tumors). In a study with BCCs obtained from a Caucasian population, 1604G?T mutation was found in 4.3% of the samples (Xie et al., 1998) . However, the ®nding of such high prevalence of the 1604G?T mutation (20.6%) in our less susceptible population might indicate that a more speci®c mutagenic agent other than UV radiation is active in Chinese populations. It is known that chronic arsenicism predisposes to various tumors, including basal cell carcinomas. A recent study (Wong et al., 1998) showed that a patient taking Chinese herbal medicine containing arsenic developed multiple basal cell carcinoma, laryngeal carcinoma, and metastatic squamous cell carcinoma. Histories of chronic arsenic intake and blood arsenic levels were not known in our studied population.
The 1604G?T SMO mutation occurred in all three histological subtypes of BCCs (Table 1) , i.e. 14 out of a total of 72 nodular (19.4%), ®ve out of a total of 16 in®ltrative (31.3%), and one out of a total of ®ve super®cial spreading (20.0%), indicating that SMO mutation is an early event of carcinogenesis. Other modifying genes may cause the dierence between these three subtypes of BCCs. While the similar ®ndings of Wicking et al. (1997) on PTCH gene phenotypes applied to the overall expression of a germ-line mutation on carcinoma occurrence and distribution, our ®ndings extend the observation of phenotype variability to the tissue level.
The 1685G?A mutation, identi®ed by AlwI restriction analysis, was not detected in any of the BCC and medulloblastoma samples, indicating that this SMO mutation is not a common one in our BCC and medulloblastoma samples.
Our ®nding of SMO mutations in over 20% of sporadic BCCs, together with the reported PTCH gene mutations in 30 ± 40% , represent a high percentage of sporadic BCCs with hedgehog signaling alterations. Further identi®cation of other gene mutations of the hedgehog signaling pathway in BCCs could reveal more alterations of this pathway in sporadic basal cell carcinomas. The ®nding of the 1604G?T mutation in medulloblastomas suggests that the sonic hedgehog-patched-smoothened signaling pathway also plays an important role in the carcinogenesis of this tumor. 
